SG11202003453QA - Method of treating acid-base disorders - Google Patents
Method of treating acid-base disordersInfo
- Publication number
- SG11202003453QA SG11202003453QA SG11202003453QA SG11202003453QA SG11202003453QA SG 11202003453Q A SG11202003453Q A SG 11202003453QA SG 11202003453Q A SG11202003453Q A SG 11202003453QA SG 11202003453Q A SG11202003453Q A SG 11202003453QA SG 11202003453Q A SG11202003453Q A SG 11202003453QA
- Authority
- SG
- Singapore
- Prior art keywords
- treating acid
- base disorders
- disorders
- base
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762581448P | 2017-11-03 | 2017-11-03 | |
US201862748363P | 2018-10-19 | 2018-10-19 | |
PCT/US2018/059093 WO2019090177A1 (en) | 2017-11-03 | 2018-11-03 | Method of treating acid-base disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003453QA true SG11202003453QA (en) | 2020-05-28 |
Family
ID=66333602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003453QA SG11202003453QA (en) | 2017-11-03 | 2018-11-03 | Method of treating acid-base disorders |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210187011A1 (en) |
EP (1) | EP3703707A4 (en) |
AU (1) | AU2018360868A1 (en) |
CA (1) | CA3080143A1 (en) |
IL (1) | IL274223A (en) |
SG (1) | SG11202003453QA (en) |
WO (1) | WO2019090177A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3003327T (en) | 2013-06-05 | 2017-12-27 | Tricida Inc. | Proton-binding polymers for oral administration |
CA3205149A1 (en) | 2014-12-10 | 2016-06-16 | Tricida, Inc. | Proton-binding polymers for oral administration |
IL262660B2 (en) | 2016-05-06 | 2024-04-01 | Tricida Inc | Compositions for and method of treating acid-base disorders |
US10934380B1 (en) | 2017-09-25 | 2021-03-02 | Tricida, Inc. | Crosslinked poly(allylamine) polymer pharmaceutical compositions |
WO2019090176A1 (en) | 2017-11-03 | 2019-05-09 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
EP4053179A1 (en) | 2021-03-01 | 2022-09-07 | Tricida Inc. | Crosslinked poly(allylamine) polymer pharmaceutical compositions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3003327T (en) * | 2013-06-05 | 2017-12-27 | Tricida Inc. | Proton-binding polymers for oral administration |
CA2929978C (en) * | 2013-11-08 | 2021-11-30 | ZS Pharma, Inc. | Microporous zirconium silicate for the treatment of hyperkalemia |
IL262660B2 (en) * | 2016-05-06 | 2024-04-01 | Tricida Inc | Compositions for and method of treating acid-base disorders |
-
2018
- 2018-11-03 CA CA3080143A patent/CA3080143A1/en active Pending
- 2018-11-03 US US16/756,735 patent/US20210187011A1/en active Pending
- 2018-11-03 EP EP18873593.0A patent/EP3703707A4/en active Pending
- 2018-11-03 AU AU2018360868A patent/AU2018360868A1/en active Pending
- 2018-11-03 WO PCT/US2018/059093 patent/WO2019090177A1/en unknown
- 2018-11-03 SG SG11202003453QA patent/SG11202003453QA/en unknown
-
2020
- 2020-04-26 IL IL274223A patent/IL274223A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20210187011A1 (en) | 2021-06-24 |
IL274223A (en) | 2020-06-30 |
WO2019090177A1 (en) | 2019-05-09 |
EP3703707A1 (en) | 2020-09-09 |
AU2018360868A1 (en) | 2020-04-30 |
CA3080143A1 (en) | 2019-05-09 |
EP3703707A4 (en) | 2021-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285151B1 (en) | Methods of treating fgf21-associated disorders | |
ZA202006746B (en) | Methods of treatment | |
IL262660A (en) | Compositions for and method of treating acid-base disorders | |
IL279308A (en) | Methods for treating hepcidin-mediated disorders | |
IL274223A (en) | Method of treating acid-base disorders | |
IL269082A (en) | Methods of treating lysosomal disorders | |
IL273960A (en) | Compositions for and method of treating acid-base disorders | |
GB2567616B (en) | Treatment method | |
IL267229A (en) | Methods of treating ocular disorders | |
EP3740201A4 (en) | Method of treating acid-base disorders | |
EP3684342C0 (en) | Method of treatment | |
GB201706406D0 (en) | Method of treatment | |
HK1247818A1 (en) | Method of treating diseases | |
GB201815588D0 (en) | Method of treatment | |
IL272092A (en) | Methods of treating behavior alterations | |
GB2571601B (en) | Treatment method | |
GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
SG11202001806TA (en) | Treatment method | |
IL270867A (en) | Treatment method | |
GB201602802D0 (en) | Method of treatment | |
SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
SG11202105877YA (en) | Method of treatment | |
GB201500555D0 (en) | Method and device for the treatment of diseases | |
GB201720439D0 (en) | Method of treatment | |
GB201718589D0 (en) | Method of treatment |